Please Wait.....
Report
Therapeutic Drug Monitoring Market by Product (Equipments,Consumables), Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs,Anti-Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029
Market Report I 2024-12-18 I 381 Pages I MarketsandMarkets
It is anticipated that the therapeutic drug monitoring market will grow from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, with a steady compound annual growth rate (CAGR) of 8.4%. Advancements in immunoassay techniques remain a key driver of this growth, influencing the sector's trajectory in a positive manner. These techniques aim to improve the accuracy, speed, and specificity of medication monitoring, including enhanced chemiluminescence, ELISA, and fluorescence enhancement. In the meantime, healthcare professionals are becoming more aware of the significance of TDM in improving therapeutic outcomes, leading to its incorporation into clinical settings. Education and training initiatives have raised clinicians' understanding of the advantages of TDM, making it easier for the technology to be implemented in everyday patient care. Collaboratively, these elements are influencing a dynamic and growing market environment.
"Consumables segment is expected to grow at the highest CAGR during the forecast period, by product."
The consumables segment holds the highest CAGR in the therapeutic drug monitoring. Consumables such as reagents, assay kits, and calibrators create a very important part in the TDM market as they are integral in routine monitoring of drugs for chronic but complex-to-cure conditions such as cancer, cardiovascular, and neurological disorders. Demand for high-quality consumables is growing as a result of the increased focus on customized therapy and the need for precise medication level evaluation. Additionally, spending money on advanced TDM systems produced by labs and hospitals would raise demand for its related goods, which would support market expansion.
"Blood segment is expected to hold the largest share of TDM market during the forecast period, by specimen."
Blood, as it is the most used specimen for TDM, fuels the market owing to its capability to provide precise and direct measurement of drug concentrations in plasma or serum. Well-established protocols in the collection and processing of blood ensure that it is reliable and consistent, while its wide clinical acceptance is well established. It is compatible with the most advanced technologies, including immunoassays and LC-MS/MS, by which drugs can be accurately quantified, meeting modern demands in therapeutic monitoring. Besides, this is supported by regulatory guidelines and clinical practices, which favor blood-based TDM; it has proved its merit in monitoring pharmacokinetics for the optimization of dose , which improves therapeutic outcomes, all combining to favor its adoption in a clinical setting.
"US to grow at the highest CAGR for North America therapeutic drug monitoring market"
The increasing prevalence in the US of chronic diseases of a cardiovascular nature, diabetes, neurological disorders, and cancer, among many others, significantly fuels this demand for TDM. Several of these disorders require thorough monitoring for the optimization of their treatment efficacy by taking measures to reduce adverse events, hence increasing the pace of adoption of TDM technologies. The well-established and well-developed healthcare framework of the country involves large numbers of hospitals, laboratories, and diagnostic centers, which further fortifies the integration of advanced end. Besides, continuous innovation in TDM technologies, supported by the presence of numerous pharmaceutical and biotech companies, ensures availability and advances in monitoring tools. These are all factors combined to spur the rapid growth of the TDM market in the US.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the therapeutic drug monitoringmarketplace.
- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level Executives - 30%, Directors - 34%, and Others - 36%
- By Region: North America- 40%, Europe - 25%, Asia Pacific- 19%, Latin America- 8%, Middle East & Africa- 6% and GCC Countries- 2%
The companies included in Therapeutic Drug Monitoring market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK), apDia Group (Belgium), BBI Solutions (UK), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), UTAK (US), Sekisui Medical Co., Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), BUHLMANN Laboratories AG (Switzerland), SJK Global, LLC (US), Epitope Diagnostics, Inc. (US), QED Bioscience Inc. (US), Boditech Med Inc. (South Korea), and Immunodiagnostic Systems (UK).
Research Coverage
This research report categorizes the therapeutic drug monitoring market by product (Equipment, and Consumables), by technology (Immunoassays, Chromatography-MS, and Other Technologies), by Drug Class (Anti-Epileptic Drugs, Anti-Arrhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Bronchodilator Drugs, Psychoactive Drugs, and Other Drug Classes), by Therapeutic Area (Neurological Disorders , Cardiology, Infectious Diseases, Oncology, Other Therapeutic Areas), by Specimen (Blood, Saliva, and other samples), by End User (Hospital Laboratories, Commercial & Private Laboratories, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Gountries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the therapeutic drug monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the therapeutic drug monitoring market. Competitive analysis of upcoming startups in the therapeutic drug monitoring market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall therapeutic drug monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Importance of therapeutic drug monitoring in organ transplant procedures, Use of therapeutic drug monitoring across various therapeutic fields, Increasing preferences for precision medicine, Growing focus on R&D related to therapeutic drug monitoring, Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, Increase in prevalence of Epilepsy, Rising prevalence of cancer to drive adoption of Therapeutic Drug Monitoring in Oncology Treatments), restraints (High capital investments, Reluctance of small hospitals to offer therapeutic drug monitoring services), opportunities (Significant opportunities in BRICS countries, Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring, Integration of AI and machine learning), and challenges (Alternatives to conventional therapeutic drug monitoring, Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries, Shortage of skilled professionals) influencing the growth of the therapeutic drug monitoring market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the therapeutic drug monitoring market
- Market Development: Comprehensive information about lucrative markets - the report analyses the therapeutic drug monitoring market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the therapeutic drug monitoring market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK)) among others in therapeutic drug monitoring market.
1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 STUDY SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY 35
1.3.3 YEARS CONSIDERED 35
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 36
1.5 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.1.1 SECONDARY DATA 38
2.1.1.1 Key data from secondary sources 39
2.1.2 PRIMARY DATA 40
2.1.2.1 Primary sources 40
2.1.2.2 Key data from primary sources 41
2.1.2.3 Key industry insights 42
2.1.2.4 Breakdown of primary interviews 43
2.2 MARKET SIZE ESTIMATION 43
2.2.1 BOTTOM-UP APPROACH 44
2.2.1.1 Approach 1: Company revenue estimation approach 44
2.2.1.2 Approach 2: Lab-based analysis 45
2.2.1.3 Approach 3: Drug class-based analysis 46
2.2.1.4 Approach 4: Presentations of companies and primary interviews 46
2.2.1.5 Growth forecast 47
2.2.1.6 CAGR projections 47
2.2.2 TOP-DOWN APPROACH 48
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 49
2.4 MARKET SHARE ASSESSMENT 50
2.5 RESEARCH ASSUMPTIONS 50
2.6 STUDY LIMITATIONS 50
2.7 GROWTH RATE ASSUMPTIONS 51
2.8 RISK ASSESSMENT 51
3 EXECUTIVE SUMMARY 52
?
4 PREMIUM INSIGHTS 58
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW 58
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE,
BY DRUG CLASS AND COUNTRY (2023) 59
4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY 60
4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029 61
4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 64
5.2.1.1 Importance of therapeutic drug monitoring in
organ transplant procedures 64
5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields 65
5.2.1.3 Increasing preference for precision medicine 67
5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring 68
5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 69
5.2.1.6 Increasing prevalence of epilepsy 70
5.2.1.7 Rising prevalence of cancer 71
5.2.2 RESTRAINTS 72
5.2.2.1 High capital investments 72
5.2.2.2 Reluctance of small hospitals to offer therapeutic
drug monitoring services 73
5.2.3 OPPORTUNITIES 73
5.2.3.1 Significant opportunities in BRICS countries 73
5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring 74
5.2.3.3 Integration of AI and machine learning 75
5.2.4 CHALLENGES 76
5.2.4.1 Alternatives to conventional therapeutic drug monitoring 76
5.2.4.2 Operational challenges and inadequate infrastructure to restrict
TDM testing in low- and middle-income countries 76
5.2.4.3 Shortage of skilled professionals 77
5.3 PRICING ANALYSIS 77
5.4 VALUE CHAIN ANALYSIS 79
5.5 SUPPLY CHAIN ANALYSIS 80
5.6 ECOSYSTEM ANALYSIS 81
5.7 REGULATORY LANDSCAPE 82
5.7.1 NORTH AMERICA 86
5.7.1.1 US 86
5.7.1.2 Canada 87
5.7.2 EUROPE 88
5.7.3 ASIA PACIFIC 88
5.7.3.1 China 88
5.7.3.2 Japan 89
5.7.3.3 India 89
5.7.4 LATIN AMERICA 90
5.7.5 MIDDLE EAST 90
5.7.6 AFRICA 90
5.8 TRADE ANALYSIS 91
5.9 PATENT ANALYSIS 92
5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026 93
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 94
5.12 TECHNOLOGY ANALYSIS 95
5.12.1 KEY TECHNOLOGY 95
5.12.1.1 Enzyme-linked immunosorbent assay 95
5.12.2 COMPLEMENTARY TECHNOLOGY 96
5.12.2.1 Liquid chromatography-mass spectrometry 96
5.12.3 ADJACENT TECHNOLOGY 96
5.12.3.1 Electrophoresis 96
5.13 PORTER'S FIVE FORCES ANALYSIS 97
5.13.1 THREAT OF NEW ENTRANTS 98
5.13.2 INTENSITY OF COMPETITIVE RIVALRY 98
5.13.3 BARGAINING POWER OF BUYERS 98
5.13.4 BARGAINING POWER OF SUPPLIERS 98
5.13.5 THREAT OF SUBSTITUTES 98
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 99
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
5.14.2 BUYING CRITERIA 99
5.15 INVESTMENT AND FUNDING SCENARIO 100
5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC
DRUG MONITORING MARKET 100
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 102
6.1 INTRODUCTION 103
6.2 CONSUMABLES 103
6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET 103
6.3 EQUIPMENT 105
6.3.1 IMMUNOASSAY ANALYZERS 108
6.3.1.1 High efficiency to drive adoption 108
6.3.2 CHROMATOGRAPHY & MS DETECTORS 111
6.3.2.1 Technological advancements to propel growth 111
?
6.3.3 CLINICAL CHEMISTRY ANALYZERS 114
6.3.3.1 Increasing incidence of chronic and complex diseases to
drive market 114
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 117
7.1 INTRODUCTION 118
7.2 IMMUNOASSAYS 118
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS 121
7.2.1.1 Accurate measurement of target-specific proteins to drive market 121
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS 123
7.2.2.1 Rapid detection time and good specificity to support growth 123
7.2.3 FLUORESCENCE IMMUNOASSAYS 127
7.2.3.1 High operability and better sensitivity of FIAs to drive market 127
7.2.4 COLORIMETRIC IMMUNOASSAYS 130
7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment 130
7.2.5 OTHER IMMUNOASSAYS 132
7.3 CHROMATOGRAPHY-MS 134
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 137
7.3.1.1 High accuracy to drive demand for LC-MS 137
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 140
7.3.2.1 Drawbacks of GC-MS to challenge market growth 140
7.4 OTHER TECHNOLOGIES 142
8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 146
8.1 INTRODUCTION 147
8.2 ANTIEPILEPTIC DRUGS 147
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH 147
8.3 ANTIARRHYTHMIC DRUGS 150
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND 150
8.4 IMMUNOSUPPRESSANT DRUGS 154
8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION
PROCEDURES TO DRIVE MARKET 154
8.5 ANTIBIOTIC DRUGS 157
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND 157
8.6 BRONCHODILATOR DRUGS 160
8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND
FOR BRONCHODILATOR DRUG MONITORING 160
8.7 PSYCHOACTIVE DRUGS 163
8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH 163
8.8 OTHER DRUGS 166
?
9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA 170
9.1 INTRODUCTION 171
9.2 NEUROLOGICAL DISORDERS 171
9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO
PROPEL MARKET 171
9.3 CARDIOLOGY 174
9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 174
9.4 INFECTIOUS DISEASES 176
9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND 176
9.5 ONCOLOGY 179
9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET 179
9.6 OTHER THERAPEUTIC AREAS 182
10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 185
10.1 INTRODUCTION 186
10.2 BLOOD 186
10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET 186
10.3 SALIVA 188
10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET 188
10.4 OTHER SAMPLES 190
11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 193
11.1 INTRODUCTION 194
11.2 HOSPITAL LABORATORIES 194
11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS
PERFORMED TO DRIVE MARKET 194
11.3 COMMERCIAL & PRIVATE LABORATORIES 197
11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES 197
11.4 OTHER END USERS 199
12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 202
12.1 INTRODUCTION 203
12.2 NORTH AMERICA 203
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 204
12.2.2 US 210
12.2.2.1 Increasing awareness regarding precision medicine to propel market 210
12.2.3 CANADA 215
12.2.3.1 Availability of funding for research to offer growth opportunities 215
?
12.3 EUROPE 220
12.4 EUROPE: MACROECONOMIC OUTLOOK 221
12.4.1 GERMANY 226
12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth 226
12.4.2 UK 230
12.4.2.1 Increasing cases of chronic diseases to drive market 230
12.4.3 FRANCE 235
12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand 235
12.4.4 ITALY 239
12.4.4.1 Rising incidence of cancer to drive demand 239
12.4.5 SPAIN 244
12.4.5.1 Adoption of technologically advanced immunoassays to
boost market 244
12.4.6 REST OF EUROPE 249
12.5 ASIA PACIFIC 253
12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK 253
12.6.1 JAPAN 259
12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market 259
12.6.2 CHINA 264
12.6.2.1 Rising number of organ transplants to boost market 264
12.6.3 INDIA 268
12.6.3.1 Rising incidence of cancer to propel market 268
12.6.4 AUSTRALIA 273
12.6.4.1 High healthcare expenditure and favorable government
initiatives to propel market 273
12.6.5 REST OF ASIA PACIFIC 278
12.7 LATIN AMERICA 282
12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET 282
12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK 284
12.8 MIDDLE EAST & AFRICA 288
12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET 288
12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 290
12.9 GCC COUNTRIES 294
12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH 294
12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK 296
?
13 COMPETITIVE LANDSCAPE 301
13.1 OVERVIEW 301
13.2 RIGHT TO WIN 301
13.3 STRATEGIES ADOPTED BY KEY PLAYERS 301
13.4 REVENUE ANALYSIS 303
13.5 MARKET SHARE ANALYSIS 304
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS 305
13.6.1 STARS 306
13.6.2 EMERGING LEADERS 306
13.6.3 PERVASIVE PLAYERS 306
13.6.4 PARTICIPANTS 306
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 308
13.6.5.1 Company footprint 308
13.6.5.2 Region footprint 308
13.6.5.3 Product footprint 309
13.6.5.4 Technology footprint 309
13.6.5.5 End-user footprint 310
13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES 310
13.7.1 PROGRESSIVE COMPANIES 310
13.7.2 RESPONSIVE COMPANIES 310
13.7.3 DYNAMIC COMPANIES 311
13.7.4 STARTING BLOCKS 311
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 312
13.7.5.1 Detailed list of key startups/SMEs 312
13.8 COMPANY VALUATION & FINANCIAL METRICS 312
13.8.1 FINANCIAL METRICS 312
13.8.2 COMPANY VALUATION 313
13.9 PRODUCT/BRAND COMPARISON 313
13.10 COMPETITIVE SCENARIO 314
13.10.1 PRODUCT LAUNCHES 314
13.10.2 DEALS 315
13.10.3 EXPANSIONS 315
14 COMPANY PROFILES 316
14.1 KEY PLAYERS 316
14.1.1 ABBOTT 316
14.1.1.1 Business overview 316
14.1.1.2 Products offered 317
14.1.1.3 MnM view 318
14.1.1.3.1 Key strengths 318
14.1.1.3.2 Strategic choices 318
14.1.1.3.3 Weaknesses and competitive threats 318
14.1.2 THERMO FISHER SCIENTIFIC INC. 319
14.1.2.1 Business overview 319
14.1.2.2 Products offered 320
14.1.2.3 Recent developments 322
14.1.2.3.1 Product launches 322
14.1.2.3.2 Deals 322
14.1.2.4 MnM view 323
14.1.2.4.1 Key strengths 323
14.1.2.4.2 Strategic choices 323
14.1.2.4.3 Weaknesses and competitive threats 323
14.1.3 F. HOFFMANN-LA ROCHE LTD. 324
14.1.3.1 Business overview 324
14.1.3.2 Products offered 326
14.1.3.3 Recent developments 327
14.1.3.3.1 Product launches 327
14.1.3.3.2 Deals 327
14.1.3.4 MnM view 327
14.1.3.4.1 Key strengths 327
14.1.3.4.2 Strategic choices 327
14.1.3.4.3 Weaknesses and competitive threats 327
14.1.4 SIEMENS HEALTHINEERS AG 328
14.1.4.1 Business overview 328
14.1.4.2 Products offered 330
14.1.4.3 Recent developments 331
14.1.4.3.1 Product launches 331
14.1.4.3.2 Deals 332
14.1.4.4 MnM view 332
14.1.4.4.1 Key strengths 332
14.1.4.4.2 Strategic choices 332
14.1.4.4.3 Weaknesses and competitive threats 332
14.1.5 DANAHER CORPORATION 333
14.1.5.1 Business overview 333
14.1.5.2 Products offered 334
14.1.5.3 Recent developments 335
14.1.5.3.1 Product launches 335
14.1.5.3.2 Deals 336
14.1.5.4 MnM view 336
14.1.5.4.1 Key strengths 336
14.1.5.4.2 Strategic choices 336
14.1.5.4.3 Weaknesses and competitive threats 337
?
14.1.6 BIO-RAD LABORATORIES, INC. 338
14.1.6.1 Business overview 338
14.1.6.2 Products offered 339
14.1.6.3 Recent developments 341
14.1.6.3.1 Product launches 341
14.1.6.3.2 Deals 341
14.1.7 BIOMERIEUX SA 342
14.1.7.1 Business overview 342
14.1.7.2 Products offered 344
14.1.8 BIOSYNEX SA 345
14.1.8.1 Business overview 345
14.1.8.2 Products offered 346
14.1.8.3 Recent developments 347
14.1.8.3.1 Product launches 347
14.1.8.3.2 Deals 347
14.1.9 GRIFOLS, S.A. 348
14.1.9.1 Business overview 348
14.1.9.2 Products offered 350
14.1.9.3 Recent developments 350
14.1.9.3.1 Deals 350
14.1.10 EXAGEN INC. 351
14.1.10.1 Business overview 351
14.1.10.2 Products offered 352
14.1.10.3 Recent developments 352
14.1.10.3.1 Deals 352
14.1.11 ARK DIAGNOSTICS, INC. 353
14.1.11.1 Business overview 353
14.1.11.2 Products offered 353
14.1.12 R-BIOPHARM AG 355
14.1.12.1 Business overview 355
14.1.12.2 Products offered 355
14.1.12.3 Recent developments 356
14.1.12.3.1 Product launches 356
14.1.13 RANDOX LABORATORIES LTD. 357
14.1.13.1 Business overview 357
14.1.13.2 Products offered 357
14.2 OTHER PLAYERS 359
14.2.1 APDIA GROUP 359
14.2.2 BBI SOLUTIONS 359
14.2.3 EAGLE BIOSCIENCES, INC. 360
14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS 362
14.2.5 AALTO SCIENTIFIC, LTD. 362
14.2.6 IMMUNDIAGNOSTIK AG 363
14.2.7 UTAK 364
14.2.8 SEKISUI MEDICAL CO., LTD. 365
14.2.9 DIASYSTEM SCANDINAVIA AB 366
14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED 367
14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH 367
14.2.12 BUHLMANN LABORATORIES AG 368
14.2.13 SJK GLOBAL, LLC 368
14.2.14 EPITOPE DIAGNOSTICS, INC. 369
14.2.15 QED BIOSCIENCE INC. 369
14.2.16 BODITECH MED INC. 370
14.2.17 IMMUNODIAGNOSTIC SYSTEMS 371
15 APPENDIX 372
15.1 DISCUSSION GUIDE 372
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 377
15.3 CUSTOMIZATION OPTIONS 379
15.4 RELATED REPORTS 379
15.5 AUTHOR DETAILS 380
TABLE 1 RISK ASSESSMENT: THERAPEUTIC DRUG MONITORING MARKET 51
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING 66
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 70
TABLE 4 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS,
BY TYPE 78
TABLE 5 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS,
BY KEY PLAYER, 2022-2024 78
TABLE 6 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS,
BY KEY REGION 79
TABLE 7 THERAPEUTIC DRUG MONITORING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 82
TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 12 IMPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL
AND CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD MILLION) 91
TABLE 13 EXPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL
AND CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD MILLION) 91
TABLE 14 LIST OF CONFERENCES AND EVENTS, 2025-2026 93
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET: PORTER'S FIVE FORCES ANALYSIS 97
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 99
TABLE 17 KEY BUYING CRITERIA FOR END USERS 100
TABLE 18 AI APPLICATIONS IN THERAPEUTIC DRUG MONITORING 101
TABLE 19 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 103
TABLE 20 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION,
2022-2029 (USD MILLION) 104
TABLE 21 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 104
TABLE 22 EUROPE: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 23 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 105
TABLE 24 DRUGS MONITORED USING ANALYTICAL EQUIPMENT 106
TABLE 25 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 106
TABLE 26 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION,
2022-2029 (USD MILLION) 107
TABLE 27 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 107
TABLE 28 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 29 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY COUNTRY, 2022-2029 (USD MILLION) 108
TABLE 30 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS,
BY REGION, 2022-2029 (USD MILLION) 109
TABLE 31 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 32 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 33 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION) 110
TABLE 34 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES,
BY COMPANY, 2020-2024 111
TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY &
MS DETECTORS, BY REGION, 2022-2029 (USD MILLION) 112
TABLE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION) 112
TABLE 37 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 38 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022-2029 (USD MILLION) 113
TABLE 39 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022-2029 (USD MILLION) 114
TABLE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION) 115
TABLE 41 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION) 115
TABLE 42 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022-2029 (USD MILLION) 116
TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 118
TABLE 44 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 119
TABLE 45 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION) 119
TABLE 46 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 47 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS,
BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 48 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 120
TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022-2029 (USD MILLION) 122
TABLE 50 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 122
TABLE 51 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 52 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 123
TABLE 53 EXAMPLES OF CLIA SYSTEMS 124
TABLE 54 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS 124
TABLE 55 THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION) 125
TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY,
2022-2029 (USD MILLION) 125
TABLE 57 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 126
TABLE 58 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY,
2022-2029 (USD MILLION) 126
TABLE 59 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE
POLARIZATION IMMUNOASSAYS 127
TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION) 128
TABLE 61 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 128
TABLE 62 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 63 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 129
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION) 130
TABLE 65 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 66 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 131
TABLE 67 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 132
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS,
BY REGION, 2022-2029 (USD MILLION) 133
TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 133
TABLE 70 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 134
TABLE 71 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION) 134
TABLE 72 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 135
TABLE 73 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY REGION, 2022-2029 (USD MILLION) 136
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION) 136
TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION) 137
TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022-2029 (USD MILLION) 137
TABLE 77 THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION) 138
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR
LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY,
2022-2029 (USD MILLION) 139
TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY,
2022-2029 (USD MILLION) 139
TABLE 80 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY,
2022-2029 (USD MILLION) 140
TABLE 81 THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION) 141
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY,
2022-2029 (USD MILLION) 141
TABLE 83 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY,
2022-2029 (USD MILLION) 142
TABLE 84 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY,
2022-2029 (USD MILLION) 142
TABLE 85 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2022-2029 (USD MILLION) 143
TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 144
TABLE 87 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 144
TABLE 88 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION) 145
TABLE 89 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 147
TABLE 90 DOSAGE GUIDELINES FOR NEW ANTIEPILEPTIC DRUGS IN
ADOLESCENTS AND ADULTS 148
TABLE 91 THERAPEUTIC DRUG MONITORING: LIMITATIONS FACED IN
NEW ANTIEPILEPTIC DRUGS 149
TABLE 92 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS,
BY REGION, 2022-2029 (USD MILLION) 149
TABLE 93 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 149
TABLE 94 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 95 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 150
TABLE 96 CLASSIFICATION OF ANTIARRHYTHMIC THERAPIES 151
TABLE 97 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS,
BY REGION, 2022-2029 (USD MILLION) 152
TABLE 98 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 152
TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 100 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 153
TABLE 101 COMMONLY USED IMMUNOSUPPRESSANT DRUGS IN ORGAN TRANSPLANTS 154
TABLE 102 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022-2029 (USD MILLION) 155
TABLE 103 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 156
TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 157
TABLE 106 EXAMPLES OF ANTIBIOTIC DRUGS 157
TABLE 107 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIAL LEVELS IN BIOFLUIDS 158
TABLE 108 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2022-2029 (USD MILLION) 159
TABLE 109 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 159
TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS,
BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 160
TABLE 112 EXAMPLES OF BRONCHODILATOR DRUGS 161
TABLE 113 THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS,
BY REGION, 2022-2029 (USD MILLION) 161
TABLE 114 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 162
TABLE 116 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 163
TABLE 117 EXAMPLES OF PSYCHOACTIVE DRUGS 164
TABLE 118 THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS,
BY REGION, 2022-2029 (USD MILLION) 164
TABLE 119 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 165
TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 166
TABLE 122 EXAMPLES OF OTHER DRUGS 167
TABLE 123 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY REGION, 2022-2029 (USD MILLION) 167
TABLE 124 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022-2029 (USD MILLION) 168
TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS,
BY COUNTRY, 2022-2029 (USD MILLION) 168
TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS,
BY COUNTRY, 2022-2029 (USD MILLION) 169
TABLE 127 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 171
TABLE 128 PREVALENCE OF NEUROLOGICAL DISORDERS 172
TABLE 129 THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS,
BY REGION, 2022-2029 (USD MILLION) 172
TABLE 130 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 173
TABLE 131 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 173
TABLE 132 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION) 174
TABLE 133 THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY REGION,
2022-2029 (USD MILLION) 175
TABLE 134 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION) 175
TABLE 135 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 136 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 176
TABLE 137 THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2022-2029 (USD MILLION) 177
TABLE 138 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 178
TABLE 139 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 178
TABLE 140 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION) 179
TABLE 141 INCREASING INCIDENCE OF CANCER, BY REGION,
2022 VS. 2030 VS. 2040 (MILLION) 180
TABLE 142 THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY REGION,
2022-2029 (USD MILLION) 180
TABLE 143 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 181
TABLE 144 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 181
TABLE 145 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY,
BY COUNTRY, 2022-2029 (USD MILLION) 182
TABLE 146 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2022-2029 (USD MILLION) 183
TABLE 147 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 183
TABLE 148 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 149 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022-2029 (USD MILLION) 184
TABLE 150 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 186
TABLE 151 THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION) 187
TABLE 152 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) 187
TABLE 153 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 154 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) 188
TABLE 155 THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY REGION, 2022-2029 (USD MILLION) 189
TABLE 156 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) 189
TABLE 157 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES,
BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 158 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION) 190
TABLE 159 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION) 191
TABLE 160 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 191
TABLE 161 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS,
BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 162 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION) 192
TABLE 163 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 194
TABLE 164 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES,
BY REGION, 2022-2029 (USD MILLION) 195
TABLE 165 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 166 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 196
TABLE 167 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 197
TABLE 168 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2022-2029 (USD MILLION) 198
TABLE 169 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 198
TABLE 170 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 171 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION) 199
TABLE 172 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION) 200
TABLE 173 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 200
TABLE 174 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS,
BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 175 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION) 201
TABLE 176 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2022-2029 (USD MILLION) 203
TABLE 177 NORTH AMERICA: KEY MACROINDICATORS 204
TABLE 178 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 206
TABLE 179 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 206
TABLE 180 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2022-2029 (USD MILLION) 206
TABLE 181 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 207
TABLE 182 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 207
TABLE 183 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 208
TABLE 184 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 208
TABLE 185 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 209
TABLE 186 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 209
TABLE 187 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION) 209
TABLE 188 FDA NOVEL DRUG THERAPY APPROVALS FOR 2023 210
TABLE 189 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS 211
TABLE 190 US: NUMBER OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY TESTS,
2022-2029 (MILLION) 212
TABLE 191 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 212
TABLE 192 US: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 212
TABLE 193 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 213
TABLE 194 US: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 195 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY TYPE, 2022-2029 (USD MILLION) 213
TABLE 196 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 214
TABLE 197 US: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 214
TABLE 198 US: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 215
TABLE 199 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 215
TABLE 200 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 216
TABLE 201 CANADA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 217
TABLE 202 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 217
TABLE 203 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2029 (USD MILLION) 217
TABLE 204 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 218
TABLE 205 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 218
TABLE 206 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 219
TABLE 207 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 219
TABLE 208 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 219
TABLE 209 EUROPE: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 220
TABLE 210 EUROPE: KEY MACROINDICATORS 221
TABLE 211 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 222
TABLE 212 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 222
TABLE 213 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 222
TABLE 214 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 223
TABLE 215 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2029 (USD MILLION) 223
TABLE 216 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 224
TABLE 217 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 224
TABLE 218 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 225
TABLE 219 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 225
TABLE 220 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 225
TABLE 221 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 227
TABLE 222 GERMANY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 227
TABLE 223 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 227
TABLE 224 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2029 (USD MILLION) 228
TABLE 225 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 228
TABLE 226 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 229
TABLE 227 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 229
TABLE 228 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 230
TABLE 229 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 230
TABLE 230 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 231
TABLE 231 UK: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 232
TABLE 232 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 232
TABLE 233 UK: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 232
TABLE 234 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY TYPE, 2022-2029 (USD MILLION) 233
TABLE 235 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 233
TABLE 236 UK: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 234
TABLE 237 UK: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 234
TABLE 238 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 234
TABLE 239 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 236
TABLE 240 FRANCE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 236
TABLE 241 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 236
TABLE 242 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2029 (USD MILLION) 237
TABLE 243 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 237
TABLE 244 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 238
TABLE 245 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 238
TABLE 246 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 239
TABLE 247 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 239
TABLE 248 ITALY: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 240
TABLE 249 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 241
TABLE 250 ITALY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 241
TABLE 251 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 241
TABLE 252 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 242
TABLE 253 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 242
TABLE 254 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 243
TABLE 255 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 243
TABLE 256 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 244
TABLE 257 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 244
TABLE 258 SPAIN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 245
TABLE 259 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 245
TABLE 260 SPAIN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 246
TABLE 261 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 246
TABLE 262 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 246
TABLE 263 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 247
TABLE 264 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 247
TABLE 265 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 248
TABLE 266 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 248
TABLE 267 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 248
TABLE 268 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 249
TABLE 269 REST OF EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2022-2029 (USD MILLION) 250
TABLE 270 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 250
TABLE 271 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 250
TABLE 272 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 251
TABLE 273 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 251
TABLE 274 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 252
TABLE 275 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 252
TABLE 276 REST OF EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION) 252
TABLE 277 ASIA PACIFIC: KEY MACROINDICATORS 253
TABLE 278 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2022-2029 (USD MILLION) 255
TABLE 279 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 255
TABLE 280 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 255
TABLE 281 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 256
TABLE 282 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 256
TABLE 283 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 257
TABLE 284 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 257
TABLE 285 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 258
TABLE 286 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 258
TABLE 287 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 258
TABLE 288 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 259
TABLE 289 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 260
TABLE 290 JAPAN: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 260
TABLE 291 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 261
TABLE 292 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 261
TABLE 293 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 262
TABLE 294 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 262
TABLE 295 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 263
TABLE 296 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 263
TABLE 297 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 263
TABLE 298 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 265
TABLE 299 CHINA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 265
TABLE 300 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 265
TABLE 301 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 266
TABLE 302 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 266
TABLE 303 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 267
TABLE 304 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 267
TABLE 305 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 268
TABLE 306 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 268
TABLE 307 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 270
TABLE 308 INDIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2022-2029 (USD MILLION) 270
TABLE 309 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 270
TABLE 310 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 311 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 271
TABLE 312 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 272
TABLE 313 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA,
2022-2029 (USD MILLION) 272
TABLE 314 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 273
TABLE 315 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 273
TABLE 316 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 274
TABLE 317 AUSTRALIA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 274
TABLE 318 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2022-2029 (USD MILLION) 275
TABLE 319 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS,
BY TYPE, 2022-2029 (USD MILLION) 275
TABLE 320 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 276
TABLE 321 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS,
2022-2029 (USD MILLION) 276
TABLE 322 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 277
TABLE 323 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN,
2022-2029 (USD MILLION) 277
TABLE 324 AUSTRALIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2022-2029 (USD MILLION) 277
TABLE 325 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 279
TABLE 326 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 279
TABLE 327 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET,
BY TECHNOLOGY, 2022-2029 (USD MILLION) 279
TABLE 328 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 329 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 280
TABLE 330 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 281
TABLE 331 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET,
BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 281
TABLE 332 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 282
TABLE 333 REST OF ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION) 282
TABLE 334 LATIN AMERICA: KEY MACROINDICATORS 284
TABLE 335 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2022-2029 (USD MILLION) 284
TABLE 336 LATIN AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 285
TABLE 337 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 285
TABLE 338 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 286
TABLE 339 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 286
TABLE 340 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 287
TABLE 341 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 287
TABLE 342 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 288
TABLE 343 LATIN AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION) 288
TABLE 344 MIDDLE EAST & AFRICA: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045 289
TABLE 345 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 290
TABLE 346 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET,
BY PRODUCT, 2022-2029 (USD MILLION) 291
TABLE 347 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022-2029 (USD MILLION) 291
TABLE 348 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET,
BY TECHNOLOGY, 2022-2029 (USD MILLION) 291
TABLE 349 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 350 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 292
TABLE 351 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 293
TABLE 352 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET,
BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 293
TABLE 353 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET,
BY SPECIMEN, 2022-2029 (USD MILLION) 294
TABLE 354 MIDDLE EAST & AFRICA: THERAPEUTIC DRUG MONITORING MARKET,
BY END USER, 2022-2029 (USD MILLION) 294
TABLE 355 GCC COUNTRIES: CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2045 295
TABLE 356 GCC COUNTRIES: KEY MACROINDICATORS 296
TABLE 357 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022-2029 (USD MILLION) 297
TABLE 358 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2022-2029 (USD MILLION) 297
TABLE 359 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION) 297
TABLE 360 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022-2029 (USD MILLION) 298
TABLE 361 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022-2029 (USD MILLION) 298
TABLE 362 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022-2029 (USD MILLION) 299
TABLE 363 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022-2029 (USD MILLION) 299
TABLE 364 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022-2029 (USD MILLION) 300
TABLE 365 GCC COUNTRIES: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022-2029 (USD MILLION) 300
TABLE 366 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS,
JANUARY 2021-NOVEMBER 2024 301
TABLE 367 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION 304
TABLE 368 THERAPEUTIC DRUG MONITORING MARKET: REGION FOOTPRINT 308
TABLE 369 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT FOOTPRINT 309
TABLE 370 THERAPEUTIC DRUG MONITORING MARKET: TECHNOLOGY FOOTPRINT 309
TABLE 371 THERAPEUTIC DRUG MONITORING MARKET: END-USER FOOTPRINT 310
TABLE 372 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF
KEY STARTUPS/SMES 312
TABLE 373 THERAPEUTIC DRUG MONITORING MARKET: PRODUCT LAUNCHES,
JANUARY 2021-NOVEMBER 2024 314
TABLE 374 THERAPEUTIC DRUG MONITORING MARKET: DEALS, JANUARY 2021-
NOVEMBER 2024 315
TABLE 375 THERAPEUTIC DRUG MONITORING MARKET: EXPANSIONS,
JANUARY 2021-NOVEMBER 2024 315
TABLE 376 ABBOTT: COMPANY OVERVIEW 316
TABLE 377 ABBOTT: PRODUCTS OFFERED 317
TABLE 378 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 319
TABLE 379 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 320
TABLE 380 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024 322
TABLE 381 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-OCTOBER 2024 322
TABLE 382 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 324
TABLE 383 CURRENCY CONVERSION FOR F. HOFFMANN-LA ROCHE LTD. 325
TABLE 384 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 326
TABLE 385 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2021-
OCTOBER 2024 327
TABLE 386 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-OCTOBER 2024 327
TABLE 387 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 328
TABLE 388 CURRENCY CONVERSION FOR SIEMENS HEALTHINEERS AG 329
TABLE 389 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 330
TABLE 390 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021-
OCTOBER 2024 331
TABLE 391 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-OCTOBER 2024 332
TABLE 392 DANAHER CORPORATION: COMPANY OVERVIEW 333
TABLE 393 DANAHER CORPORATION: PRODUCTS OFFERED 334
TABLE 394 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024 335
TABLE 395 DANAHER CORPORATION: DEALS, JANUARY 2021-OCTOBER 2024 336
TABLE 396 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 338
TABLE 397 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 339
TABLE 398 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2021-
OCTOBER 2024 341
TABLE 399 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-OCTOBER 2024 341
TABLE 400 BIOMERIEUX SA: COMPANY OVERVIEW 342
TABLE 401 CURRENCY CONVERSION FOR BIOMERIEUX SA 343
TABLE 402 BIOMERIEUX SA: PRODUCTS OFFERED 344
TABLE 403 BIOSYNEX SA: COMPANY OVERVIEW 345
TABLE 404 CURRENCY CONVERSION FOR BIOSYNEX SA 346
TABLE 405 BIOSYNEX SA: PRODUCTS OFFERED 346
TABLE 406 BIOSYNEX SA: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024 347
TABLE 407 BIOSYNEX SA: DEALS, JANUARY 2021-OCTOBER 2024 347
TABLE 408 GRIFOLS, S.A.: COMPANY OVERVIEW 348
TABLE 409 GRIFOLS, S.A.: PRODUCTS OFFERED 350
TABLE 410 GRIFOLS, S.A.: DEALS, JANUARY 2021-OCTOBER 2024 350
TABLE 411 EXAGEN INC.: COMPANY OVERVIEW 351
TABLE 412 EXAGEN INC.: PRODUCTS OFFERED 352
TABLE 413 EXAGEN INC.: DEALS, JANUARY 2021-OCTOBER 2024 352
TABLE 414 ARK DIAGNOSTICS, INC.: COMPANY OVERVIEW 353
TABLE 415 ARK DIAGNOSTICS, INC.: PRODUCTS OFFERED 353
TABLE 416 R-BIOPHARM AG: COMPANY OVERVIEW 355
TABLE 417 R-BIOPHARM AG: PRODUCTS OFFERED 355
TABLE 418 R-BIOPHARM AG: PRODUCT LAUNCHES, JANUARY 2021-OCTOBER 2024 356
TABLE 419 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 357
TABLE 420 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED 357
TABLE 421 APDIA GROUP: COMPANY OVERVIEW 359
TABLE 422 BBI SOLUTIONS: COMPANY OVERVIEW 359
TABLE 423 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW 360
TABLE 424 JASEM LABORATORY SYSTEMS AND SOLUTIONS: COMPANY OVERVIEW 362
TABLE 425 AALTO SCIENTIFIC, LTD.: COMPANY OVERVIEW 362
TABLE 426 IMMUNDIAGNOSTIK AG: COMPANY OVERVIEW 363
TABLE 427 UTAK: COMPANY OVERVIEW 364
TABLE 428 SEKISUI MEDICAL CO., LTD.: COMPANY OVERVIEW 365
TABLE 429 DIASYSTEM SCANDINAVIA AB: COMPANY OVERVIEW 366
TABLE 430 CAMBRIDGE LIFE SCIENCES LIMITED: COMPANY OVERVIEW 367
TABLE 431 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: COMPANY OVERVIEW 367
TABLE 432 BUHLMANN LABORATORIES AG: COMPANY OVERVIEW 368
TABLE 433 SJK GLOBAL, LLC: COMPANY OVERVIEW 368
TABLE 434 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW 369
TABLE 435 QED BIOSCIENCE INC.: COMPANY OVERVIEW 369
TABLE 436 BODITECH MED INC.: COMPANY OVERVIEW 370
TABLE 437 IMMUNODIAGNOSTIC SYSTEMS: COMPANY OVERVIEW 371
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security